Eye injury, inflammatory
diseases, and exposure to toxic chemicals such as pesticides and acids used in
manufacturing processes are some of the major causes of uveitis. Anterior
uveitis is an inflammation of the middle part of the eye, which further
includes the other vital part responsible for the vision such as iris, ciliary
body, and other adjacent tissues.
The global Uveitis
Treatment Market is estimated to account for US$ 648.4 Mn in terms of value
in 2020 and is expected to reach US$ 1,036.0 Mn by the end of 2027.
Global Uveitis Treatment Market:
Drivers
Positive outcomes in clinical
trials are expected to propel growth of the global uveitis treatment over the
forecast period. For instance, in June 2019, Alimera Sciences, Inc. announced
three-year follow-up data from the Phase 3 clinical trial for ILUVIEN 190
micrograms intravitreal implant in applicator, for the prevention of relapse in
recurrent non-infectious uveitis affecting the posterior segment of the eye.
Global Uveitis Treatment Market:
Opportunities
R&D in uveitis is expected to
offer lucrative growth opportunities for players in the global uveitis
treatment over the forecast period. For instance, in May 2020, researchers from
National Cheng Kung University, Taiwan, identified a novel role of reactive
oxygen species in the pathogenesis of experimental autoimmune uveitis and
suggested a potential antioxidant role for the treatment of autoimmune uveitis
in the future.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1094
Global Uveitis Treatment Market:
Restraints
Insufficient funding for R&D
in eye health is expected to hinder growth of the market. For instance,
according to Peter McCluskey, Professor of Clinical Ophthalmology and Eye
Health, and Director of Save Sight Institute at the Faculty of Medicine and
Health at the University of Sydney, (as reported to MI Vision, an ophthalmic
journal, in July 2019), research grants from the National Health and Medical
Research Council (Australia) are down from 30% to around 7%.
Key Takeaways:
The global uveitis treatment
market was valued at US$ 605.7 Mn in 2019 and is forecast to reach a value of
US$ 1,036.0 Mn by 2027 at a CAGR of 6.9% between 2020 and 2027. Major factor
driving the growth of global uveitis treatment market during the forecast
period include high prevalence of uveitis, and number of treatment options.
Corticosteroids held dominant
position in the global uveitis treatment market in 2019, accounting for 21.1%
share in terms of value, followed by Monoclonal Antibodies and Antibiotics,
respectively. Corticosteroids are a primary treatment options for treating
uveitis, and can be administered via multiple routes such as topical, and oral.
Market Trends
The market is witnessing virtual
conferences due to Covid-19. For instance, in June 2020, EyePoint
Pharmaceuticals, Inc. presented at the Jefferies Virtual Healthcare Conference.
Major players in the market are
focused on adopting partnership strategies to enhance their market share. For
instance, in March 2020, Clearside Biomedical, Inc. partnered with Arctic
Vision, a company focused on developing and commercializing innovative
ophthalmology therapies in China and Asia, under which Arctic Vision will get
an exclusive license for the commercialization and development of XIPERE
(triamcinolone acetonide suprachoroidal injectable suspension for the treatment
of macular edema associated with uveitis) in Greater China (mainland China,
Hong Kong, Macau and Taiwan) and South Korea.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/uveitis-treatment-market-1094
Global Uveitis Treatment Market:
Competitive Landscape
Major players operating in the
global uveitis treatment market include, Allergan, Inc., Novartis AG, Valeant
Pharmaceuticals International, Inc., Galapagos, EyePoint Pharmaceuticals, Inc.,
Clearside Biomedical, Inc., AbbVie Inc., Tarsius Pharma, Eyegate Pharmaceuticals, Inc., Alimera Sciences
Inc., and pSivida Corp.
Global Uveitis Treatment Market:
Key Developments
April 2020: Alimera Sciences,
Inc. reported that international net revenue increased 23% to approximately US$
7.5 million in Q1 2020, compared to approximately US$ 6.1 million for the same
period during 2019, owing to growth in the company’s DME business in direct
markets and the launches of ILUVIEN’s uveitis indication in Germany and the U.K.
in the second half of 2019.
April 2020: Clearside Biomedical,
Inc. and Bausch Health amended and revised their partnership for XIPERE
(triamcinolone acetonide suprachoroidal injectable suspension for the treatment
of macular edema associated with uveitis), under which Bausch + Lomb has been
granted exclusive options for the right to commercialize and develop XIPERE in
Europe and the U.K., Australia and New Zealand, and South America and Mexico.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1094
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment